Welcome to our dedicated page for Merus news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus stock.
Merus N.V. (MRUS) is a clinical-stage biotechnology company pioneering bispecific antibody therapeutics for cancer treatment through its Biclonics® platform. This page provides investors and researchers with centralized access to official announcements, clinical trial updates, and strategic developments shaping the company's trajectory in immuno-oncology.
Find timely updates on Merus' investigational therapies, including progress across multiple cancer indications. Track key milestones such as regulatory feedback, partnership expansions with pharmaceutical collaborators, and financial performance updates. Our aggregation ensures efficient monitoring of material events without promotional bias.
Content spans clinical data disclosures, research collaborations with industry leaders like Incyte and Lilly, intellectual property developments, and financial reporting. Each update is categorized for quick scanning while maintaining technical accuracy required for biotech analysis.
Bookmark this page for streamlined access to Merus' evolving story in multispecific antibody development. Combine our news repository with SEC filings and scientific publications for comprehensive investment research approach.
Merus N.V. (Nasdaq: MRUS) reported its Q1 2022 financial results, indicating a total revenue increase to $11.7 million from $8.4 million in Q1 2021, driven by collaboration revenue growth. The company ended Q1 with cash reserves of $384.3 million, down from $430.8 million at year-end 2021. Net loss for the quarter was $18.9 million, slightly improving from a loss of $10.2 million year-over-year. Merus is excited about its upcoming ASCO presentation on Zenocutuzumab, highlighting its ongoing clinical trials and pipeline growth. Cash runway is expected to last beyond 2024.
Merus N.V. (Nasdaq: MRUS) announced that an abstract showcasing interim clinical data for zenocutuzumab (Zeno), a bispecific antibody targeting NRG1+ cancer, has been selected for oral presentation at the 2022 ASCO Annual Meeting in Chicago from June 3-7, 2022. The presentation, titled 'Efficacy and safety of zenocutuzumab,' will take place on June 5. Merus is currently conducting the phase 1/2 eNRGy trial and will discuss updated interim data during a conference call on the same day.
Merus N.V. (Nasdaq: MRUS) announced the publication of a preclinical report on its bispecific antibody, petosemtamab (Peto, MCLA-158), in Nature Cancer. The report highlights Peto's potent growth inhibition of colorectal cancer organoids and its unique mechanism that triggers EGFR degradation in LGR5-expressing organoids. Peto shows promising results compared to cetuximab, with superior growth inhibition in KRAS mutant CRC models. The company is currently enrolling patients for a Phase 1 trial and plans a clinical update in the second half of 2022.
Merus N.V. (MRUS) announced promising preclinical data for MCLA-129, highlighting its ability to promote Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cell-Mediated Phagocytosis (ADCP) in non-small cell lung cancer (NSCLC). The findings, which show MCLA-129's significant inhibition of growth in a patient-derived EGFR exon20 insertion tumor model, will be presented at the AACR Annual Meeting 2022. Currently, MCLA-129 is in a phase 1/2 clinical trial, with updates anticipated in the second half of 2022.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that its CEO, Bill Lundberg, M.D., will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 13 from 10:15-10:55 a.m. ET. The event will be accessible via a live webcast on the Company's investor page, with an archived version available afterward. Merus specializes in developing innovative multispecific antibodies, including its unique Biclonics® and Triclonics®, which show promise in clinical studies.
Rallybio Corporation announces significant changes to its Board of Directors. Christine Nash and Hui Liu have been appointed as new members, bringing extensive experience in rare diseases and business development, respectively. Tim Shannon, M.D. will resign from the Board, effective at the 2022 Annual Meeting of Shareholders. The company aims to leverage the expertise of new board members to advance its product portfolio for rare diseases.
Merus N.V. (MRUS) has announced the upcoming presentation of a poster discussing the mechanism and effectiveness of its drug MCLA-129 at the AACR Annual Meeting 2022 on April 10. MCLA-129 targets EGFR and c-MET, critical in treating non-small cell lung cancer (NSCLC). Currently, MCLA-129 is in a phase 1/2 clinical trial aimed at assessing safety, tolerability, and clinical activity in patients with advanced tumors. Merus has a collaboration with Betta Pharmaceuticals for its development in China while retaining global rights outside the region.
Merus N.V. (Nasdaq: MRUS) reported financial results for 2021, revealing a net loss of $66.8 million.
Collaboration revenue increased to $49.1 million, up from $29.9 million in 2020, driven by substantial contributions from Lilly and Incyte. Research and development expenses rose to $98.2 million, reflecting higher costs related to zenocutuzumab (Zeno) and MCLA-129. The company ended the year with cash, cash equivalents, and marketable securities of $430.7 million, projected to sustain operations beyond 2024. Clinical updates for Zeno, petosemtamab, and MCLA-129 are expected in 2022.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will participate in several upcoming investor conferences. These include the Guggenheim Healthcare Talks/2022 Oncology Conference on February 10, the Citi 2022 Virtual Immuno-Oncology Summit on February 16, and the 11th Annual SVB Leerink Global Healthcare Conference on February 17. Webcasts of these events will be available on the Company's Investors page, with archived presentations accessible for a limited time.
Merus N.V. (Nasdaq: MRUS) has appointed Shannon Campbell as the Executive Vice President & Chief Commercial Officer, effective February. With over 25 years of experience in pharmaceuticals, Campbell aims to enhance Merus's commercial strategy for its lead candidate, zenocutuzumab, and its pipeline of innovative antibodies. Additionally, Merus has regained global rights to MCLA-145 following Incyte's decision to opt-out of ex-U.S. development, providing an opportunity to advance this candidate in solid tumors.
FAQ
What is the current stock price of Merus (MRUS)?
What is the market cap of Merus (MRUS)?
